Current Knowledge of Buprenorphine and Its Unique Pharmacological Profile
- Medicine, BiologyPain practice : the official journal of World Institute of Pain
Buprenorphine exhibits a pronounced antihyperalgesic effect that might indicate potential advantages in the treatment of neuropathic pain, and its favorable safety profile and proven efficacy in severe pain and favorable tolerability mean that it can be considered a safe and effective option for treating chronic cancer and noncancer pain.
Buprenorphine – an attractive opioid with underutilized potential in treatment of chronic pain
- Biology, MedicineJournal of pain research
Mounting evidence from clinical studies and conclusions drawn by a panel of experts strongly support superior safety and efficacy profile of buprenorphine vs marketed opioids.
Buprenorphine 5, 10 and 20 μg/h Transdermal Patch
- Medicine, BiologyDrugs
Transdermal buprenorphine has generally demonstrated good efficacy and tolerability in clinical trials in chronic non-malignant pain, providing effective background analgesia as part of pain management strategies for patients with osteoarthritis, low back pain and other persistent pain syndromes of at least moderate severity.
Transdermal buprenorphine – a critical appraisal of its role in pain management
- Medicine, BiologyJournal of pain research
Mounting evidence indicates the appropriateness of Bup TDS in the treatment of diverse acute and chronic pain syndromes which have been less or not responsive to other opioids.
Safety and Efficacy of Buprenorphine Patch in the Management of Chronic Pain
A transdermal formulation of buprenorphine was introduced in 2001, which reignited interest in this medication for the treatment of chronic moderate-to-severe pain. This review presents the evidence…
Effect of transdermal opioids in experimentally induced superficial, deep and hyperalgesic pain
- Medicine, BiologyBritish journal of pharmacology
This work has compared the analgesic and anti‐hyperalgesic effects of buprenorphine and fentanyl.
Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option
- Biology, MedicineDrugs
Although originally designed as an analgesic, buprenorphine has mainly been used for opioid maintenance therapy and only now is increasingly recognized as an effective analgesic with an improved therapeutic index relative to certain potent opioids.
Clinical Use of Buprenorphine for Anesthesia and Pain Management in Japan
- Medicine, Biology
Buprenorphine is useful for postoperative pain relief in patients with severe liver dysfunction in Japan, however, the prolonged metabolism of BUP and occurrence of delayed emergence from anesthesia may occur in these patients.
Buprenorphine—Clinically useful but often misunderstood
- Medicine, BiologyScandinavian journal of pain
Understanding transdermal buprenorphine and a practical guide to its use for chronic cancer and non-cancer pain management.
- MedicineJournal of opioid management
An overview of TDB is presented and practical recommendations for its use as part of a multifaceted strategy in chronic cancer and non-cancer pain are provided.
SHOWING 1-10 OF 140 REFERENCES
The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic.
- Biology, MedicineDrug and alcohol dependence
Transdermal buprenorphine in the management of persistent pain – safety aspects
- Biology, MedicineTherapeutics and clinical risk management
Transdermal buprenorphine (Gruenenthal GmbH, Aachen, Germany) provides a noninvasive method of rate-controlled drug release ensuring constant and predictable serum bupenorphine levels over a prolonged period, which has been shown to be advantageous for long-term treatment of chronic pain patients providing reliable pain control, few adverse events, and good patient acceptance.
Buprenorphine: considerations for pain management.
- Medicine, BiologyJournal of pain and symptom management
Is there a ceiling effect of transdermal buprenorphine? Preliminary data in cancer patients
- Medicine, BiologySupportive Care in Cancer
In six patients, dose increments of TD-BUP were effective, and patients achieved adequate analgesia within 6 days, and it cannot be excluded that even higher doses may be effective, as some patients required rapid titration with higher morphine equivalent doses.
Buprenorphine in cancer pain
- Biology, MedicineSupportive Care in Cancer
The recent development of a polymer matrix patch delivery system for buprenorphine prevents “dose dumping” and facilitates pain management in those unable to take oral analgesics.
Transdermal buprenorphine in pain management – experiences from clinical practice: five case studies
- MedicineInternational journal of clinical practice
Four cases of chronic, non‐malignant pain, and one case of chronic cancer pain were presented and transdermal buprenorphine matrix patches provided effective analgesia and were well tolerated.
Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction.
- Medicine, BiologyArchives of general psychiatry
Buprenorphine has potential for treating narcotic addiction since it is acceptable to addicts, is long-acting, produces a low level of physical dependence such that patients may be easily detoxified, is less toxic than drugs used for maintenance therapy, and blocks the effects of narcotics.
Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial.
- MedicineClinical therapeutics
Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine.
- MedicineJournal of pain and symptom management
Transdermal buprenorphine. Commentaries
- Medicine, Biology
Despite the availability of rescue medication to all patients, those receiving transdermal buprenorphine tended to experience greater pain relief, reduced pain intensity and longer pain-free sleep, and the requirement for rescue medication was reduced from baseline in >50% of patients treated with transderMAL bupenorphine, in two trials.